Evidence map›Paper›PMID 28851844›Full record

ArticlemBio2017

The New Xpert MTB/RIF Ultra: Improving Detection of

Soumitesh Chakravorty, Ann Marie Simmons, Mazhgan Rowneki, Heta Parmar, Yuan Cao, Jamie Ryan, Padmapriya P Banada, Srinidhi Deshpande, Shubhada Shenai, Alexander Gall and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 393 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
393citing papers in PubMed, 6 pooled it
35.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

393 citing papers in PubMed, 6 syntheses or guidelines pooled it, 640 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Clinical performance of the Abbott RealTime Mycobacterium tuberculosis (MTB) PCR on bronchoscopic specimens for diagnosing pulmonary tuberculosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Prevalence and Predictors of Tuberculosis in Adults and Adolescents With Sputum Trace Ultra Results in 2 High-Burden Clinical Settings.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  17. Review
  18. Monocyte-Amplified Transcriptional Signatures of Human Diseases.bioRxiv : the preprint server for biology · 2026
    Article
  19. Article
  20. Article

333 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 7 institutions in 6 countries.

Soumitesh ChakravortyDepartment of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA chakraso@njms.rutgers.edu allandda@njms.rutgers.edu.
Ann Marie SimmonsCepheid Inc., Sunnyvale, California, USA.
Mazhgan RownekiDepartment of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Heta ParmarDepartment of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Yuan CaoDepartment of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Jamie RyanCepheid Inc., Sunnyvale, California, USA.
Padmapriya P BanadaDepartment of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Srinidhi DeshpandeDepartment of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Shubhada ShenaiDepartment of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Alexander GallCepheid Inc., Bothell, Washington, USA.
Jennifer GlassCepheid Inc., Sunnyvale, California, USA.
Barry KrieswirthPublic Health Research Institute, Rutgers, New Jersey Medical School, Newark, New Jersey, USA.
Samuel G SchumacherFoundation for Innovative New Diagnostics, Geneva, Switzerland.
Pamela NabetaFoundation for Innovative New Diagnostics, Geneva, Switzerland.
Nestani TukvadzeNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
Camilla RodriguesP. D. Hinduja National Hospital and Medical Research Centre, Mumbai, India.
Alena SkrahinaNational Reference Laboratory, Republican Scientific and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus.
Elisa TaglianiEmerging Bacterial Pathogens Unit, San Raffaele Scientific Institute, Milan, Italy.
Daniela M CirilloEmerging Bacterial Pathogens Unit, San Raffaele Scientific Institute, Milan, Italy.
Amy DavidowDepartment of Preventive Medicine and Community Health, Rutgers, New Jersey Medical School, Newark, New Jersey, USA.
Claudia M DenkingerFoundation for Innovative New Diagnostics, Geneva, Switzerland.
David PersingCepheid Inc., Sunnyvale, California, USA.
Robert KwiatkowskiCepheid Inc., Sunnyvale, California, USA.
Martin JonesCepheid Inc., Sunnyvale, California, USA.
David AllandDepartment of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA chakraso@njms.rutgers.edu allandda@njms.rutgers.edu.
Rutgers New Jersey Medical SchoolFoundation for Innovative New Diagnostics · CHRutgers, The State University of New Jersey · USSan Raffaele University of Rome · ITNational Center for Tuberculosis and Lung Disease · GENational Hospital · INRepublican Scientific and Practical Centre of Pulmonology and Tuberculosis · BY

Funding

Pre-clinical Development of an Advanced Genexpert Test for Drug Resistant MtbR01AI111397 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI ALLAND, DAVID · 2014 to 2018
$6.2M
Emory-Georgia TB Research Training ProgramD43TW007124 · FIC · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Nestani Tukvadze · 2004 to 2026
$4.6M
FIC NIH HHS D43 TW007124NIAID NIH HHS R01 AI111397
6 · The paper itself

Abstract

The Xpert MTB/RIF assay (Xpert) is a rapid test for tuberculosis (TB) and rifampin resistance (RIF-R) suitable for point-of-care testing. However, it has decreased sensitivity in smear-negative sputum, and false identification of RIF-R occasionally occurs. We developed the Xpert MTB/RIF Ultra assay (Ultra) to improve performance. Ultra and Xpert limits of detection (LOD), dynamic ranges, and RIF-R

Indexed as

Point-of-Care TestingAntibiotics, AntitubercularBacterial ProteinsDNA-Directed RNA PolymerasesHumansLimit of DetectionMolecular Diagnostic TechniquesMutationMycobacterium tuberculosisPolymerase Chain ReactionRifampinSensitivity and SpecificitySputumTuberculosisTuberculosis, PulmonaryAntibiotics, AntitubercularBacterial ProteinsDNA-Directed RNA PolymerasesRifampinrpoB protein, Mycobacterium tuberculosisdiagnosissensitivetuberculosisXpert MTB/RIF Ultra

Identifiers

PMID28851844
PMCPMC5574709
OpenAlexW2753668595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.